definiens: means ( i ) the JV Information and Documentation ( not including the Intellectual Property Rights of Olym pus ), ( ii ) all confidential or proprietary information previously provided by Cytori to [COMPANY] pursuant to the Related Agreements that was marked as confidential if in written ( including electronic ) form, or if in oral form, was followed by a writing conf irming that the information is within thirty ( 30 ) Business Days after oral disclosure, ( iii ) all confidential or proprietary information that Cytori provided to [COMPANY] pursuant to this Agreement that is marked as confidential if in written ( including electronic ) form, or if in oral form, is followed by a writing confirming that the information is within thirty ( 30 ) Business Days after oral disclosure, ( iv ) the following written or electronic materials [COMPANY] received from Cyt ori relating or pertaining to the JV and the development of the Final Celution Devices, Celution One Device, Celution One Consumables and Deliverables whether or not such written or electronic materials are marked or confirmed as confidential : - i - ( a ) diagrams, drawings, schematics or plans and software ( including specifications therefore ) ; ( b ) all documentation, protocols, and reports relating to laboratory studies and feasibility experiments related to device development or adipose -related research ; ( c ) manufacturing documentation, material specifications, and supplier lists and information ; ( d ) second source manufacturing records and documents ; ( e ) all documents and records relating or pertaining to Cytori ’s proprietary enzymes and reagents including Celase and Intravase ; ( f ) technical service documentation and forms ; ( g ) regulatory documents and filings ( technical files, and all submissions to FDA, BSi, DEKRA, MHLW, and other global regul atory bodies including all supporting documentation ) ; ( h ) quality system documents and records including electronic files and records on QCBD ; ( i ) financial documents, including spreadsheets and summaries ; ( j ) descriptions or summaries of Cytori IP, IP opinions and correspondence or other communications relating to Cytori IP ( including any information and correspondence related to the 231 patent ) ; ( k ) all documents related to any Cytori -sponsored preclinical studies ; and ( l ) all documents and records concerning Cytori ’s past or present clinical trials, including, but not limited to, the Restore 1, Restore 2, Apollo, Precise, Athena, and Advance trials, as well as any such records relating to any investigator initiated trials inv olving the Celution 600 & Celution 800, Puregraft or the Celution One Device